Clinical Trials Browser

Phase 2 × Active not recruiting × Uterine Cervical Neoplasms × Clear all

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT00188539 2026-03-06

Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Phase 2 Active not recruiting

GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

NCT05063916 2026-02-27

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Phase 2 Active not recruiting

Carcinoma, Uterine Cervical Neoplasms

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06238635 2026-01-13

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06416696 2026-01-02

Toripalimab for High-risk Locally Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04141449 2025-12-31

Potlako+

Phase 2 Active not recruiting

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Acquired Immunodeficiency Syndrome, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Neoplasms, Vulvar Neoplasms

NCT03614949 2025-12-19

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02257528 2025-09-08

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Active not recruiting

26 enrolled 12 charts

Uterine Cervical Neoplasms

NCT03833479 2025-05-21

ATOMICC

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04516616 2025-03-20

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04487587 2025-02-26

COMICE

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT03894215 2025-02-20

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05032040 2025-02-07

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Phase 2 Active not recruiting

GenitourinaryGynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06771596 2025-01-13

CC11

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05682950 2024-11-21

Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03340376 2024-07-03

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05051696 2024-06-04

Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Phase 2 Active not recruiting

Uterine Cervical Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT06419673 2024-05-17

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT02490748 2016-02-23

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms